Diamanti-Kandarakis E - Search Results

1

Tailoring treatment for PCOS phenotypes.

Papadakis G, Kandaraki EA, Garidou A, Koutsaki M, Papalou O, Diamanti-Kandarakis E, Peppa M. Papadakis G, et al. Among authors: diamanti kandarakis e. Expert Rev Endocrinol Metab. 2021 Jan;16(1):9-18. doi: 10.1080/17446651.2021.1865152. Epub 2020 Dec 31. Expert Rev Endocrinol Metab. 2021. PMID: 33382003

2

Is cardiovascular risk in women with PCOS a real risk? Current insights.

Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Papadakis G, et al. Minerva Endocrinol. 2017 Dec;42(4):340-355. doi: 10.23736/S0391-1977.17.02609-8. Epub 2017 Jan 31. Minerva Endocrinol. 2017. PMID: 28146139 Review.

3

The role of stress in PCOS.

Papalou O, Diamanti-Kandarakis E. Papalou O, et al. Expert Rev Endocrinol Metab. 2017 Jan;12(1):87-95. doi: 10.1080/17446651.2017.1266250. Epub 2016 Dec 7. Expert Rev Endocrinol Metab. 2017. PMID: 30058880

4

Implications and Future Perspectives of AGEs in PCOS Pathophysiology.

Merhi Z, Kandaraki EA, Diamanti-Kandarakis E. Merhi Z, et al. Trends Endocrinol Metab. 2019 Mar;30(3):150-162. doi: 10.1016/j.tem.2019.01.005. Epub 2019 Feb 1. Trends Endocrinol Metab. 2019. PMID: 30712978 Review.

5

Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).

Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, Panidis D. Diamanti-Kandarakis E, et al. Clin Endocrinol (Oxf). 2008 Oct;69(4):634-41. doi: 10.1111/j.1365-2265.2008.03247.x. Epub 2008 Mar 19. Clin Endocrinol (Oxf). 2008. PMID: 18363886

6

Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS).

Diamanti-Kandarakis E, Argyrakopoulou G, Economou F, Kandaraki E, Koutsilieris M. Diamanti-Kandarakis E, et al. J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):242-6. doi: 10.1016/j.jsbmb.2008.03.014. Epub 2008 Mar 12. J Steroid Biochem Mol Biol. 2008. PMID: 18440223 Review.

7

Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.

Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Diamanti-Kandarakis E, et al. Eur J Endocrinol. 2010 Feb;162(2):193-212. doi: 10.1530/EJE-09-0733. Epub 2009 Oct 19. Eur J Endocrinol. 2010. PMID: 19841045 Review.

8

Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome.

Androulakis II, Kandaraki E, Christakou C, Karachalios A, Marinakis E, Paterakis T, Diamanti-Kandarakis E. Androulakis II, et al. Clin Endocrinol (Oxf). 2014 Sep;81(3):426-31. doi: 10.1111/cen.12447. Epub 2014 Apr 15. Clin Endocrinol (Oxf). 2014. PMID: 24601936

9

Oxidative Stress in Polycystic Ovary Syndrome.

Papalou O, Victor VM, Diamanti-Kandarakis E. Papalou O, et al. Curr Pharm Des. 2016;22(18):2709-22. doi: 10.2174/1381612822666160216151852. Curr Pharm Des. 2016. PMID: 26881435 Review.

10

Endocrine Disrupting Chemicals: An Occult Mediator of Metabolic Disease.

Papalou O, Kandaraki EA, Papadakis G, Diamanti-Kandarakis E. Papalou O, et al. Front Endocrinol (Lausanne). 2019 Mar 1;10:112. doi: 10.3389/fendo.2019.00112. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 30881345 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page